A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors

Summary Background Trametinib is an inhibitor of MEK1/MEK2 activation and kinase activity. In order to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of single-agent trametinib (part 1) and trametinib in combination with gemcitabine (part 2), we undertook the first cli...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2015-10, Vol.33 (5), p.1058-1067
Hauptverfasser:	Kasuga, Akiyoshi, Nakagawa, Kazuhiko, Nagashima, Fumio, Shimizu, Toshio, Naruge, Daisuke, Nishina, Shinichi, Kitamura, Hiroshi, Kurata, Takayasu, Takasu, Atsuko, Fujisaka, Yasuhito, Okamoto, Wataru, Nishimura, Yuichiro, Mukaiyama, Akihira, Matsushita, Hideki, Furuse, Junji
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine triphosphate Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Area Under Curve Asian Continental Ancestry Group Cancer Cancer therapies Clinical trials Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Dose-Response Relationship, Drug Drug dosages Drug Therapy, Combination FDA approval Female Gemcitabine Hospitals Humans Inhibitor drugs Japan Kinases Lung diseases Male Maximum Tolerated Dose Medicine Medicine & Public Health Middle Aged Mutation Neoplasms - drug therapy Oncology Pancreatic cancer Pancreatic Neoplasms - drug therapy Patients Pharmacokinetics Pharmacology/Toxicology Phase I Studies Pyridones - administration & dosage Pyridones - adverse effects Pyridones - pharmacokinetics Pyridones - therapeutic use Pyrimidinones - administration & dosage Pyrimidinones - adverse effects Pyrimidinones - pharmacokinetics Pyrimidinones - therapeutic use Side effects Solid tumors Studies Targeted cancer therapy Toxicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!